Control group:Temozolomide

5 trials

Sponsors

Beijing Tiantan Hospital, Capital Medical University, Huashan Hospital Affiliated to Fudan University, Huashan Hospital affiliated to Fudan University, Fujian Cancer Hospital

Conditions

Glioblastoma MultiformeGlioblastoma multiformeGliomaRecurrent GBMglioblastoma

Early Phase 1

To evaluate the safety and efficacy of wearable glioma electric field therapy combined with temozolomide in the treatment of recurrent glioblastoma (GBM): a randomized, controlled, open-label, multicenter trial.

Active, not recruitingChiCTR2000034285

Beijing Tiantan Hospital, Capital Medical UniversityRecurrent GBM

Start: 2020-07-20Updated: 2020-07-06

Phase 2

Semusine-Temozolomide Combination Therapy versus Temozolomide Therapy Chemoradiotherapy / Adjuvant Chemotherapy in Patients with Newly Diagnosed Glioblastoma: a Phase I /II Trial

Active, not recruitingChiCTR2100041612

Fujian Cancer Hospitalglioblastoma

Start: 2021-06-01Updated: 2021-03-22

Phase 3

Multicenter phase 3 clinical study of early surgical treatment of recurrent asymptomatic glioblastomas

RecruitingChiCTR2000037350

Huashan Hospital affiliated to Fudan UniversityGlioma

Start: 2020-10-01Updated: 2020-10-19

Unknown Phase

Prospective, multicenter, open, randomized, parallel controlled trial for tumor treating fields (EFE-G100) combined with temozolomide versus temozolomide alone in patients with newly diagnosed glioblastoma

Active, not recruitingChiCTR2000034706

Huashan Hospital Affiliated to Fudan UniversityGlioblastoma multiforme

Start: 2020-07-09Updated: 2020-07-27

Evaluate the efficacy and safety of Tumor Eletric Field Therapy System in the treatment of newly diagnosed supratentorial glioblastoma

RecruitingChiCTR2100047049

Beijing Tiantan Hospital, Capital Medical UniversityGlioblastoma Multiforme

Start: 2021-06-10Updated: 2022-01-18